These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 34504492)

  • 1. Validation of a Triplex Pharmacokinetic Assay for Simultaneous Quantitation of HIV-1 Broadly Neutralizing Antibodies PGT121, PGDM1400, and VRC07-523-LS.
    Wesley MS; Chiong KT; Seaton KE; Arocena CA; Sawant S; Hare J; Hernandez K; Rojas M; Heptinstall J; Beaumont D; Crisafi K; Nkolola J; Barouch DH; Sarzotti-Kelsoe M; Tomaras GD; Yates NL
    Front Immunol; 2021; 12():709994. PubMed ID: 34504492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial.
    Sobieszczyk ME; Mannheimer S; Paez CA; Yu C; Gamble T; Theodore DA; Chege W; Yacovone M; Hanscom B; Heptinstall J; Seaton KE; Zhang L; Miner MD; Eaton A; Weiner JA; Mayer K; Kalams S; Stephenson K; Julg B; Caskey M; Nussenzweig M; Gama L; Barouch DH; Ackerman ME; Tomaras GD; Huang Y; Montefiori D;
    Lancet HIV; 2023 Oct; 10(10):e653-e662. PubMed ID: 37802566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials.
    Mkhize NN; Yssel AEJ; Kaldine H; van Dorsten RT; Woodward Davis AS; Beaume N; Matten D; Lambson B; Modise T; Kgagudi P; York T; Westfall DH; Giorgi EE; Korber B; Anthony C; Mapengo RE; Bekker V; Domin E; Eaton A; Deng W; DeCamp A; Huang Y; Gilbert PB; Gwashu-Nyangiwe A; Thebus R; Ndabambi N; Mielke D; Mgodi N; Karuna S; Edupuganti S; Seaman MS; Corey L; Cohen MS; Hural J; McElrath MJ; Mullins JI; Montefiori D; Moore PL; Williamson C; Morris L
    PLoS Pathog; 2023 Jun; 19(6):e1011469. PubMed ID: 37384759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial.
    Julg B; Stephenson KE; Wagh K; Tan SC; Zash R; Walsh S; Ansel J; Kanjilal D; Nkolola J; Walker-Sperling VEK; Ophel J; Yanosick K; Borducchi EN; Maxfield L; Abbink P; Peter L; Yates NL; Wesley MS; Hassell T; Gelderblom HC; deCamp A; Mayer BT; Sato A; Gerber MW; Giorgi EE; Gama L; Koup RA; Mascola JR; Monczor A; Lupo S; Rolle CP; Arduino R; DeJesus E; Tomaras GD; Seaman MS; Korber B; Barouch DH
    Nat Med; 2022 Jun; 28(6):1288-1296. PubMed ID: 35551291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralization diversity of HIV-1 Indian subtype C envelopes obtained from cross sectional and followed up individuals against broadly neutralizing monoclonal antibodies having distinct gp120 specificities.
    Mullick R; Sutar J; Hingankar N; Deshpande S; Thakar M; Sahay S; Ringe RP; Mukhopadhyay S; Patil A; Bichare S; Murugavel KG; Srikrishnan AK; Goyal R; Sok D; Bhattacharya J
    Retrovirology; 2021 May; 18(1):12. PubMed ID: 33990195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subtle Longitudinal Alterations in Env Sequence Potentiate Differences in Sensitivity to Broadly Neutralizing Antibodies following Acute HIV-1 Subtype C Infection.
    Mandizvo T; Gumede N; Ndlovu B; Ndlovu S; Mann JK; Chopera DR; Singh L; Dong KL; Walker BD; Ndhlovu ZM; Lavine CL; Seaman MS; Gounder K; Ndung'u T
    J Virol; 2022 Dec; 96(24):e0127022. PubMed ID: 36453881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trial.
    Walsh SR; Gay CL; Karuna ST; Hyrien O; Skalland T; Mayer KH; Sobieszczyk ME; Baden LR; Goepfert PA; Del Rio C; Pantaleo G; Andrew P; Karg C; He Z; Lu H; Paez CA; Baumblatt JAG; Polakowski LL; Chege W; Anderson MA; Janto S; Han X; Huang Y; Dumond J; Ackerman ME; McDermott AB; Flach B; Piwowar-Manning E; Seaton K; Tomaras GD; Montefiori DC; Gama L; Mascola JR;
    PLoS Med; 2024 Jun; 21(6):e1004329. PubMed ID: 38913710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A sensitive method to quantify HIV-1 antibodies in mucosal samples.
    Prabhakaran M; Narpala S; Andrews SF; O'Connell S; Lin CL; Coates EE; Flach B; Ledgerwood JE; McDermott AB
    J Immunol Methods; 2021 Apr; 491():112995. PubMed ID: 33582148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Broadly neutralizing monoclonal antibodies for HIV prevention.
    Miner MD; Corey L; Montefiori D
    J Int AIDS Soc; 2021 Nov; 24 Suppl 7(Suppl 7):e25829. PubMed ID: 34806308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Randomised Clinical Trial of the Safety and Pharmacokinetics of VRC07-523LS Administered via Different Routes and Doses (HVTN 127/HPTN 087).
    Walsh SR; Gay CL; Karuna ST; Hyrien O; Skalland T; Mayer KH; Sobieszczyk ME; Baden LR; Goepfert PA; Del Rio C; Pantaleo G; Andrew P; Karg C; He Z; Lu H; Paez CA; Baumblatt JAG; Polakowski LL; Chege W; Janto S; Han X; Huang Y; Dumond J; Ackerman ME; McDermott AB; Flach B; Piwowar-Manning E; Seaton K; Tomaras GD; Montefiori DC; Gama L; Mascola JR;
    medRxiv; 2024 Jan; ():. PubMed ID: 38260276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic Assessment of Antiviral Potency, Breadth, and Synergy of Triple Broadly Neutralizing Antibody Combinations against Simian-Human Immunodeficiency Viruses.
    Berendam SJ; Styles TM; Morgan-Asiedu PK; Tenney D; Kumar A; Obregon-Perko V; Bar KJ; Saunders KO; Santra S; De Paris K; Tomaras GD; Chahroudi A; Permar SR; Amara RR; Fouda GG
    J Virol; 2021 Jan; 95(3):. PubMed ID: 33177194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Coreceptor-Mimetic Peptide Enhances the Potency of V3-Glycan Antibodies.
    Fetzer I; Davis-Gardner ME; Gardner MR; Alfant B; Weber JA; Prasad NR; Zhou AS; Farzan M
    J Virol; 2019 Mar; 93(5):. PubMed ID: 30541842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralization Breadth and Potency of Single-Chain Variable Fragments Derived from Broadly Neutralizing Antibodies Targeting Multiple Epitopes on the HIV-1 Envelope.
    van Dorsten RT; Lambson BE; Wibmer CK; Weinberg MS; Moore PL; Morris L
    J Virol; 2020 Jan; 94(2):. PubMed ID: 31619559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-Chain Variable Fragments of Broadly Neutralizing Antibodies Prevent HIV Cell-Cell Transmission.
    van Dorsten RT; Reh L; Trkola A; Morris L; Moore PL
    J Virol; 2022 Feb; 96(4):e0193421. PubMed ID: 34935437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ex vivo sensitivity to broadly neutralizing antibodies and anti-CD4 antibody UB-421 of infectious viral isolates from people living with multidrug-resistant HIV.
    Rai MA; Blazkova J; Justement JS; Shi V; Kennedy BD; Manning MR; McLaughlin M; Sneller MC; Pau AK; Moir S; Chun TW
    EBioMedicine; 2024 Jun; 104():105151. PubMed ID: 38728839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combinations of Single Chain Variable Fragments From HIV Broadly Neutralizing Antibodies Demonstrate High Potency and Breadth.
    van Dorsten RT; Wagh K; Moore PL; Morris L
    Front Immunol; 2021; 12():734110. PubMed ID: 34603312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitivity to Broadly Neutralizing Antibodies of Recently Transmitted HIV-1 Clade CRF02_AG Viruses with a Focus on Evolution over Time.
    Stefic K; Bouvin-Pley M; Essat A; Visdeloup C; Moreau A; Goujard C; Chaix ML; Braibant M; Meyer L; Barin F
    J Virol; 2019 Jan; 93(2):. PubMed ID: 30404804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention.
    Mahomed S; Garrett N; Capparelli EV; Osman F; Harkoo I; Yende-Zuma N; Gengiah TN; Archary D; Samsunder N; Baxter C; Mkhize NN; Modise T; Carlton K; McDermott A; Moore PL; Karim QA; Barouch DH; Fast PE; Mascola JR; Ledgerwood JE; Morris L; Abdool Karim SS
    J Infect Dis; 2022 Aug; 226(3):510-520. PubMed ID: 35134995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial.
    Mahomed S; Garrett N; Karim QA; Zuma NY; Capparelli E; Baxter C; Gengiah T; Archary D; Samsunder N; Doria-Rose N; Moore P; Williamson C; Barouch DH; Fast PE; Pozzetto B; Hankins C; Carlton K; Ledgerwood J; Morris L; Mascola J; Abdool Karim S
    BMJ Open; 2020 Nov; 10(11):e042247. PubMed ID: 33243815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Bispecific Antibody That Simultaneously Recognizes the V2- and V3-Glycan Epitopes of the HIV-1 Envelope Glycoprotein Is Broader and More Potent than Its Parental Antibodies.
    Davis-Gardner ME; Alfant B; Weber JA; Gardner MR; Farzan M
    mBio; 2020 Jan; 11(1):. PubMed ID: 31937648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.